Title
Category
Credits
Event date
Cost
BRAINWeek 2022 Digital All Access
  • PAINWeek
  • 22.00 AAFP
  • 22.00 AANP
  • 22.00 ACCME (All Other)
  • 22.00 ACCME (MD/DO Only)
  • 22.00 ACPE Pharmacy
  • 22.00 ANCC
  • 22.00 APA
$499.00
The enormity of CNS-related conditions poses an immense burden to public health. In 2022, there remain significant knowledge gaps among clinicians treating neurologic and psychiatric disorders. Conditions such as dementia, epilepsy, migraine, MS, and stroke require a more inclusive approach to continuing medical education.The BRAINWeek 2022 Digital All Access agenda has been crafted to address the most frequently diagnosed conditions encountered in clinical practice, with an emphasis on collaborative care among specialists and frontline practitioners. 
Skin of Color Symposium: Dermatology Pearls for Treating Pediatric Patients of Color
  • LivDerm
  • TME
  • 1.75 AAPA Category I CME
  • 1.75 AMA PRA Category 1 Credit™
  • 1.75 ANCC
  • 1.75 Participation
$0.00
Pediatric patients with melanin-rich skin, or skin of color (SOC), can be disproportionately affected by numerous dermatologic conditions. Patients can be more susceptible or have a greater disease burden, especially with conditions such as acne, atopic dermatitis, psoriasis, pigmentary disorders, and hair disorders.
Clinical Brief: IL-13 inhibitors: Advances and Considerations for Managing Moderate-to-Severe Atopic Dermatitis
  • LivDerm
  • TME
  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 ANCC
  • 0.25 Participation
$0.00
Timely and adequate treatment of atopic dermatitis (AD) is essential for helping to promote better long-term outcomes and quality of life and may help prevent the development of other atopic conditions.
Webcast Series: Optimizing Long-Term Weight Loss in Patients with Type 2 Diabetes: Advances and Expert Perspectives
  • CMHC
  • TME
$0.00
The increasing prevalence and impacts of overweight and obesity in patients with type 2 diabetes renders weight loss and weight loss maintenance an important part of treatment goals. In this 6-part webcast series, chaired by Robert H. Eckel, MD and Donna Ryan, MD, you will have a chance to hear from experts on the comprehensive management of obesity in patients with type 2 diabetes, including lifestyle modifications, the spectrum of pharmacotherapy and metabolic surgery, as well as how to practically apply these concepts to patient care.
Digital Pathway - The Evolving Landscape of LDL-C Reduction in High Risk Patients: Optimizing Combination Therapy to Reduce ASCVD Risk
  • CMHC
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
$0.00
Lowering LDL-C effectively and safely is paramount to prevent and lower the risk of recurrent ASCVD events. Even with the advances in LDL-C lowering therapy, LDL-C goal achievement is low, and clinical inertia and patient non-adherence are major factors for continued ASCVD residual risk. The landscape of LDL-C lowering therapy is rapidly evolving, with several new and emerging agents that may help address these gaps.
Webcast: Screening, Diagnosis and Treatment of IDA in NDD-CKD
  • CMHC
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
$0.00
Iron deficiency anemia (IDA) is a common condition in patients with non–dialysis-dependent chronic kidney disease (NDD-CKD) that can affect quality of life and lead to suboptimal outcomes. Despite the impacts of IDA in NDD-CKD patients, its screening, diagnosis, and treatment remains challenging. Recent trials and evidence has shown that i.v. iron supplementation for the treatment of IDA might be beneficial in this setting, and during this webcast,, experts will discuss important advances and considerations about the screening, diagnosis, and treatment of IDA in patients with NDD-CKD.
Webcast: Challenging Cases in NDD-CKD patients with IDA
  • CMHC
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
$0.00
Iron deficiency anemia (IDA) is the most common cause of anemia in patients with non–dialysis-dependent chronic kidney disease (NDD-CKD) and addressing this condition is important in the overall management of these patients. During this webcast, expert faculty utilize challenging cases to discuss important clinical pearls about the screening, diagnosis and treatment of IDA in NDD-CKD.This activity is part of the IDA in NDD-CKD Digital Education Hub.
Hunting for Better Outcomes: Management Options for Huntington’s Disease
  • 0.50 ACCME (All Other)
  • 0.50 ACCME (MD/DO Only)
  • 0.50 ACPE Pharmacy
  • 0.50 ANCC
$0.00
Huntington’s disease (HD) is a rare, progressive, genetic disorder resulting in a breakdown of nerve cells in the brain. Many types of clinicians are involved in the patient journey because HD affects movement, behavior, memory loss, impulse control, and the ability to do the simplest self-care activities. This multimedia activity provides the collaborative care team of neurologists, psychiatrists, and allied healthcare providers with an improved understanding of the fundamentals of HD, its chronic burden, and how to treat patients accordingly. Hunting for Better Outcomes provides HCPs with an enhanced understanding of HD and tools for improving overall patient outcomes.
Webcast: Challenging Cases in Lipid Lowering: Interpreting the Evidence to Patient Care
  • CMHC
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
$0.00
Expert faculty developed three challenging cases that illustrate practical points about the current challenges of optimizing LDL-C lowering therapy, as well as how to optimize treatment with statin and non-statin therapies. In addition, the cases serve to offer clinical pearls on how the newer therapies fit into the treatment landscape and inform patient selection. During the webcast, expert faculty engage in interactive discussions to offer additional perspectives and clinical pearls.
Virtual Symposium - Optimizing Lipid Lowering Therapy in Women: Gaps, Perspectives, and Advances
  • CMHC
  • 0.75 ACPE Pharmacy
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC
  • 0.75 Participation
$0.00
Atherosclerotic cardiovascular disease (ASCVD) events are among the leading causes of death in women in the US and globally. Even with advances in LDL-C (low-density lipoprotein cholesterol) lowering therapy, LDL-C goal achievement in high-risk women is lower than that in men, with clinical inertia, statin intolerance, and non-adherence being major factors for continued ASCVD residual risk.

Pages